MNPR
Monopar Therapeutics Inc.
Price Chart
Latest Quote
$111.12
+2.60 (+2.40%)
Current Price
| Previous Close | $108.52 |
| Open | $106.61 |
| Day High | $111.94 |
| Day Low | $104.00 |
| Volume | 264,764 |
Stock Information
| Shares Outstanding | 6.70M |
| Total Debt | $230K |
| Cash Equivalents | $137.49M |
| Net Income | $-14.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $744.40M |
| EPS (TTM) | $-1.93 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $607.14M |
| Income | $-14.98M |
| Book/sh | $20.21 |
| Cash/sh | $20.52 |
| Employees | 22 |
Financial Ratios
| Quick Ratio | 55.94 |
| Current Ratio | 56.05 |
| Debt/Eq | 0.17 |
Returns & Margins
| ROA | -12.11% |
| ROE | -15.86% |
Ownership
| Insider Ownership | 23.42% |
| Institutional Ownership | 93.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -35.42 |
| P/B | 5.50 |
Analyst Data
| Recommendation | none |
| Target Price | $113.62 |
Technical Indicators
| SMA20 | $94.82 |
| SMA50 | $74.93 |
| SMA200 | $70.30 |
| RSI | 75.22 |
| ATR | 8.2938 |
| Shares Float | 4.12M |
| Short Float | 33.23% |
| Short Ratio | 10.11 |
| Volatility | 1.48 |
| Rel Volume | 1.22 |
Performance History
| Week | +4.24% |
| Month | +78.22% |
| Quarter | +92.58% |
| 6 Months | +59.66% |
| YTD | +68.34% |
| Year | +170.56% |
| 3 Years | +2678.00% |
| 5 Years | +288.53% |
| 10 Years | -16.14% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $111.12 | 264,764 |
| 2026-07-16 | $108.52 | 193,700 |
| 2026-07-15 | $108.69 | 177,000 |
| 2026-07-14 | $99.79 | 498,200 |
| 2026-07-13 | $103.33 | 214,700 |
| 2026-07-10 | $106.60 | 149,300 |
| 2026-07-09 | $104.50 | 336,900 |
| 2026-07-08 | $99.27 | 298,000 |
| 2026-07-07 | $95.22 | 163,600 |
| 2026-07-06 | $97.12 | 103,900 |
| 2026-07-02 | $97.79 | 188,300 |
| 2026-07-01 | $95.03 | 177,500 |
| 2026-06-30 | $92.59 | 111,800 |
| 2026-06-29 | $94.56 | 119,900 |
| 2026-06-26 | $87.68 | 310,300 |
| 2026-06-25 | $87.63 | 203,100 |
| 2026-06-24 | $88.99 | 300,300 |
| 2026-06-23 | $81.77 | 278,000 |
| 2026-06-22 | $68.66 | 126,200 |
| 2026-06-18 | $67.47 | 128,100 |
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
đ° Latest News
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
Zacks âĸ 2026-06-15T13:55:03Z
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-05-03T13:26:35Z
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.
Simply Wall St. âĸ 2026-02-11T13:06:52Z
Broadcom Stock Sees Improved Relative Strength Rating
Investor's Business Daily âĸ 2026-02-09T18:21:20Z
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
Zacks âĸ 2025-12-22T15:11:00Z
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?
Simply Wall St. âĸ 2025-11-22T12:47:30Z
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls
The Fly âĸ 2025-11-10T14:39:09Z
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
Zacks âĸ 2025-10-21T13:55:02Z
How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments
Simply Wall St. âĸ 2025-10-18T18:07:00Z
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy
Insider Monkey âĸ 2025-10-16T20:33:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $16,704,415 | $16,161,721 | $8,831,235 | $10,536,877 |
| Net Non Operating Interest Income Expense | $2,987,521 | $404,020 | $429,039 | $21,239 |
| Operating Expense | $16,704,415 | $16,161,721 | $8,831,235 | $10,536,877 |
| General And Administrative Expense | $6,800,190 | $3,155,735 | $3,231,042 | $2,945,276 |
| Other Income Expense | - | $171,282 | - | - |
| Other Non Operating Income Expenses | - | $171,282 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Net Interest Income | $2,987,521 | $404,020 | $429,039 | $21,239 |
| Interest Income | $2,987,521 | $404,020 | $429,039 | $21,239 |
| Normalized Income | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Net Income From Continuing And Discontinued Operation | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Total Operating Income As Reported | $-16,704,415 | $-16,161,721 | $-8,831,235 | $-10,536,877 |
| Net Income Common Stockholders | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Net Income | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Net Income Including Noncontrolling Interests | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Net Income Continuous Operations | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Pretax Income | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Interest Income Non Operating | $2,987,521 | $404,020 | $429,039 | $21,239 |
| Operating Income | $-16,704,415 | $-16,161,721 | $-8,831,235 | $-10,536,877 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.85 | $-4.11 | $-3.04 | $-4.15 |
| Basic EPS | $-1.85 | $-4.11 | $-3.04 | $-4.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,704,415 | $-16,161,721 | $-8,831,235 | $-10,536,877 |
| EBITDA (Bullshit earnings) | $-16,704,415 | $-16,161,721 | $-8,831,235 | $-10,536,877 |
| EBIT | $-16,704,415 | $-16,161,721 | $-8,831,235 | $-10,536,877 |
| Diluted Average Shares | $7,411,121 | $3,790,202 | $2,764,790 | $2,543,633 |
| Basic Average Shares | $7,411,121 | $3,790,202 | $2,764,790 | $2,543,633 |
| Diluted NI Availto Com Stockholders | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Research And Development | $9,904,225 | $13,005,986 | $5,600,193 | $7,591,601 |
| Selling General And Administration | $6,800,190 | $3,155,735 | $3,231,042 | $2,945,276 |
| Other Gand A | $6,800,190 | $3,155,735 | $3,231,042 | $2,945,276 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Total Assets | $140,717,709 | $60,291,071 | $7,345,159 | $13,226,954 |
| Total Non Current Assets | $254,921 | $0 | $12,646 | $61,228 |
| Current Assets | $140,462,788 | $60,291,071 | $7,332,513 | $13,165,726 |
| Other Current Assets | $63,745 | $78,869 | $66,433 | $45,982 |
| Cash Cash Equivalents And Short Term Investments | $140,399,043 | $60,212,202 | $7,266,080 | $13,119,744 |
| Cash And Cash Equivalents | $61,833,552 | $45,816,289 | $7,266,080 | $8,186,194 |
| Debt | ||||
| Total Debt | $154,920 | $0 | $0 | $8,408 |
| Long Term Debt And Capital Lease Obligation | $154,920 | $0 | $0 | $8,408 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,890,156 | $5,254,300 | $1,757,393 | $3,137,302 |
| Total Non Current Liabilities Net Minority Interest | $154,920 | $0 | $0 | $8,408 |
| Current Liabilities | $2,735,236 | $5,254,300 | $1,757,393 | $3,128,894 |
| Payables And Accrued Expenses | $2,735,236 | $5,254,300 | $1,757,393 | $3,128,894 |
| Payables | $2,735,236 | $2,254,300 | $1,757,393 | $3,128,894 |
| Accounts Payable | $2,735,236 | $2,254,300 | $1,757,393 | $3,128,894 |
| Equity | ||||
| Common Stock Equity | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Total Equity Gross Minority Interest | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Stockholders Equity | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Gains Losses Not Affecting Retained Earnings | $131,389 | $35,992 | $-14,132 | $8,942 |
| Other Equity Adjustments | $131,389 | $35,992 | $-14,132 | $8,942 |
| Retained Earnings | $-89,509,530 | $-75,792,636 | $-60,206,217 | $-51,804,021 |
| Other | ||||
| Ordinary Shares Number | $6,692,140 | $6,102,560 | $2,980,899 | $2,589,314 |
| Share Issued | $6,692,140 | $6,102,560 | $2,980,899 | $2,589,314 |
| Tangible Book Value | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Invested Capital | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Working Capital | $137,727,552 | $55,036,771 | $5,575,120 | $10,036,832 |
| Capital Lease Obligations | $154,920 | $0 | $0 | $8,408 |
| Total Capitalization | $137,827,553 | $55,036,771 | $5,587,766 | $10,089,652 |
| Additional Paid In Capital | $227,199,002 | $130,787,312 | $65,805,134 | $61,871,784 |
| Capital Stock | $6,692 | $6,103 | $2,981 | $12,947 |
| Common Stock | $6,692 | $6,103 | $2,981 | $12,947 |
| Long Term Capital Lease Obligation | $154,920 | $0 | $0 | $8,408 |
| Current Accrued Expenses | $0 | $3,000,000 | $0 | - |
| Net PPE | $254,921 | $0 | $12,646 | $61,228 |
| Gross PPE | $254,921 | $0 | $12,646 | $61,228 |
| Other Properties | $254,921 | - | $12,646 | $61,228 |
| Other Short Term Investments | $78,565,491 | $14,395,913 | $0 | $4,933,550 |
| Buildings And Improvements | - | - | $12,646 | $61,228 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,201,291 | $-6,404,139 | $-7,858,293 | $-7,228,559 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,201,291 | $-6,404,139 | $-7,858,293 | $-7,228,559 |
| Cash Flow From Continuing Operating Activities | $-12,201,291 | $-6,404,139 | $-7,858,293 | $-7,228,559 |
| Investing Activities | ||||
| Investing Cash Flow | $-63,453,114 | $-14,338,403 | $4,927,748 | $-4,918,511 |
| Cash Flow From Continuing Investing Activities | $-63,453,114 | $-14,338,403 | $4,927,748 | $-4,918,511 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-34,999,957 | $0 | - | - |
| Issuance Of Capital Stock | $127,141,529 | $59,396,393 | $2,074,196 | $109,337 |
| Financing Cash Flow | $91,574,402 | $59,292,257 | $2,027,227 | $32,873 |
| Cash Flow From Continuing Financing Activities | $91,574,402 | $59,292,257 | $2,027,227 | $32,873 |
| Net Other Financing Charges | $-1,132,341 | $-104,220 | $-46,969 | $-76,633 |
| Net Common Stock Issuance | $92,141,572 | $59,396,393 | $2,074,196 | $109,337 |
| Common Stock Issuance | $127,141,529 | $59,396,393 | $2,074,196 | $109,337 |
| Other | ||||
| End Cash Position | $61,833,552 | $45,816,289 | $7,266,080 | $8,186,194 |
| Beginning Cash Position | $45,816,289 | $7,266,080 | $8,186,194 | $20,303,869 |
| Effect Of Exchange Rate Changes | $97,266 | $494 | $-16,796 | $-3,478 |
| Changes In Cash | $15,919,997 | $38,549,715 | $-903,318 | $-12,114,197 |
| Proceeds From Stock Option Exercised | $565,171 | $84 | $0 | $169 |
| Common Stock Payments | $-34,999,957 | $0 | - | - |
| Net Investment Purchase And Sale | $-63,453,114 | $-14,338,403 | $4,927,748 | $-4,918,511 |
| Sale Of Investment | $23,700,000 | $985,730 | $12,809,842 | $0 |
| Purchase Of Investment | $-87,153,114 | $-15,324,133 | $-7,882,094 | $-4,918,511 |
| Change In Working Capital | $-2,605,810 | $3,498,253 | $-1,353,946 | $1,645,816 |
| Change In Other Working Capital | $-9,432 | $4,238 | - | $-4,238 |
| Change In Other Current Assets | $15,404 | $-12,776 | $-20,410 | $171,755 |
| Change In Payables And Accrued Expense | $-2,611,782 | $3,506,791 | $-1,333,536 | $1,478,299 |
| Change In Accrued Expense | $-3,000,000 | $3,000,000 | $0 | - |
| Change In Payable | $388,218 | $506,791 | $-1,333,536 | $1,478,299 |
| Change In Account Payable | $388,218 | $506,791 | $-1,333,536 | $1,478,299 |
| Stock Based Compensation | $4,837,877 | $1,140,785 | $1,897,849 | $1,641,263 |
| Amortization Of Securities | $-716,464 | $-9,016 | - | - |
| Net Income From Continuing Operations | $-13,716,894 | $-15,586,419 | $-8,402,196 | $-10,515,638 |
| Other Non Cash Items | - | $4,552,258 | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-07-17